Global Health Matters

Photo courtesy of the Business Ethics for APEC SMEs Initiative
2 July 2020 - By Thomas B. Cueni
Authors: Dr. Jeff Blackmer, Mr. Thomas Cueni, Mr. Gaston Fernandez, Ms. Nancy Travis, Mr. Russell Williams The dual health and economic crisis resulting from COVID-19 has brought into sharp focus the importance of ethical business conduct. Emergency government measures, widespread economic and social disruption, as well as unscrupulous actors taking ...
Read More
4 June 2020 - By Thomas B. Cueni
Published on Thomas Cueni's LinkedIn profile. COVID-19 is not business as usual for any of us, especially not for the pharmaceutical industry. As we enter into the sixth month of the COVID-19 pandemic, I think it is no understatement to say that the global biopharmaceutical industry has been at the ...
Read More
2 June 2020 - By Thomas B. Cueni
Thomas Cueni, IFPMA Director General, spoke to BBC Sounds on 26 May on about the extent and importance of collaborations both between biopharmaceutical companies and with other stakeholders, notably universities and biotech companies to combat the COVID-19 crisis. At this stage, it is still impossible to know with certainty whether ...
Read More
Filled vials and syringe.
27 May 2020 - By
This was originally published on on Tuesday, 26 May, 2020. Throughout recent history, vaccines represent the most impactful public health advance, helping to prevent the spread of infectious diseases and, in many places, eliminating some of the most devastating conditions. As communities around the world continue to grapple with the impact ...
Read More
20 May 2020 - By
Through IFPMA's partnership with The Guardian, informed conversations about the state of global health progress in various areas were carried out with the help of experts, including academia, international actors and industry. The following series presents articles published in The Guardian Labs: The value of medicine in achieving global health progress ...
Read More
19 May 2020 - By Thomas B. Cueni
This was originally published in the Financial Times on Sunday, May 17, 2020. We must not send the wrong message to pharma companies that have taken huge risks As we confront an unprecedented public health, social and economic crisis brought about by Covid-19, our hopes are pinned on scientific innovation ...
Read More
11 May 2020 - By Thomas B. Cueni
Thomas Cueni, IFPMA Director-General, spoke to CNN about the challenges to be faced in the manufacturing of a COVID-19 vaccine on a large-scale and how the industry, as a whole, will respond to the challenges.  00:02 to 1:04 (Transcript of Thomas Cueni's part) ANNA STEWART, CNN REPORTER (AS): At least, 100 ...
Read More
8 May 2020 - By Thomas B. Cueni
Last week, high-level representatives from seven companies – Takeda, Merck, AstraZeneca, CSL Behring, MSD, Pfizer and Sandoz – took part in a second IFPMA COVID-19 virtual media briefing dedicated to the on-going R&D efforts to find a treatment for COVID-19. It was an important milestone, taking stock of all that ...
Read More
6 May 2020 - By
On Monday, 4 May 2020, David Ricks, IFPMA President and Chairman and CEO of Eli Lilly, delivered a video statement at the Global Response Pledging Conference convened by the European Commission together with the WHO (YouTube). The objective of the conference was to raise 7.5bn EUR to ramp up work ...
Read More
28 April 2020 - By
The COVID-19 pandemic has affected millions of people around the world exposed health care systems, broken down economies, and profoundly changed the way of social interactions. This pandemic cannot be tackled alone, and doesn’t leave room for any competing interests. In the words of Dr Tedros Adhanom Ghebreyesus, WHO Director-General, ...
Read More
20 April 2020 - By Jane Barratt
We sat down with Dr. Jane Barratt, Secretary General, International Federation of Ageing to discuss the adoption of a life-course approach to health system challenges; the positive impact of adult vaccination across generations; and concrete policy recommendations to prevent the onset of dementia. The Decade of Healthy Ageing(2020-2030) has begun. ...
Read More
14 April 2020 - By Nanette Cocero
This was originally published in Devex on Monday, 13 April, 2020. Behind WHO’s new strategy stands great momentum in the global health community to continue to advance the availability of lifesaving vaccines, while ensuring routine immunization can provide an effective platform to expand universal health care coverage. But to ensure ...
Read More
1 April 2020 - By
This was originally published in Pharma Boardroom on Wednesday, 1 April, 2020. The CEOs and top executives, David Ricks, Chairman and Chief Executive Officer, Eli Lilly & Co and IFPMA President, Severin Schwan, Chief Executive Officer, Roche, Paul Stoffels, Chief Scientific Officer, Johnson & Johnson, David Loew, Executive Vice-President, Sanofi ...
Read More
Scientist Working on Computer In  Modern Laboratory
NOTE TO INSPECTOR: all graps, dna models, charts are made by me
26 March 2020 - By Thomas B. Cueni
Thomas Cueni, IFPMA Director General, spoke to BBC Newshour on 19 March about the commitments made by the global pharmaceutical industry in addressing the COVID-19 global health crisis. Industry has the tools and solutions to fight and defeat the novel strain of coronavirus. In this unique situation, industry commits to tackle this issue ...
Read More
25 March 2020 - By Thomas B. Cueni
In recent weeks, we have seen an unprecedented rapid response from governments, international organisations, health care professionals, the biopharmaceutical industry and many others to respond to one of the biggest global health crisis the world has experienced in recent decades: the novel coronavirus, or so-called COVID-19. Both professionally but also ...
Read More
1 2 3 11